Barchart Demo Center



Stock Screeners




Fund Screeners

Foreign Exchange



Financial Calculators

Embedded Widgets



JSON Feeds

Symbol Overview

United States|Canada

Karyopharm Therapeut

Add to Portfolio
-0.32 (-1.82%)
as of Jan 22, 2020

Last 17.22
Change -0.32 (-1.82%)
Open 17.54
Prev. Close 17.54
Today's Range
52wk Range
Volume 1,663,100
Avg Volume 1,188,525
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
KPTI -1.82% +19.00% +87.99%
DJIA -0.03% +5.46% +19.59%
S&P 500 +0.03% +7.67% +26.16%

Key Statistics

Annual EPS -3.43
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 1,101,340
Weighted Alpha +136.60
Standard Deviation -0.52
Profit Margin N/A
Beta 2.59

Growth Rates

YTD -10.17%
1-Year +89.44%
3-Year +58.86%
5-Year -35.09%


Sell Hold Buy

Recent Headlines

Karyopharm Announces Preliminary Unaudited Fourth

GlobeNewswire via COMTEX - Mon Jan 13, 07:00AM EST
-- XPOVIO Unaudited Net Product Sales of between $17 and $18 Million for Fourth Quarter 2019 and between $30 and $31 Million for the Full Year 2019 --(full story)
KPTI: 17.22 (-0.32)

Karyopharm to Present at the 38th Annual J.P. Morgan

GlobeNewswire via COMTEX - Tue Jan 07, 07:00AM EST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on (full story)
JPM: 136.68 (-0.16), KPTI: 17.22 (-0.32)

Karyopharm Therapeutics Reports Inducement Grants

GlobeNewswire via COMTEX - Thu Jan 02, 04:05PM EST
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 25,000 s(full story)
KPTI: 17.22 (-0.32)

Karyopharm Submits New Drug Application to U.S. FDA

GlobeNewswire via COMTEX - Mon Dec 23, 07:38AM EST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for (full story)
KPTI: 17.22 (-0.32)

Karyopharm Presents XPOVIO(R) (Selinexor) and

GlobeNewswire via COMTEX - Sun Dec 08, 09:00AM EST
-- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis(R) and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with Heavily Pretreated, Kyprolis-Naive(full story)
KPTI: 17.22 (-0.32)